Four patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2039. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2039
Next term end
4
Patent families
When these terms end
Each bar runs from grant to computed term end. 2021 to 2043.
US 11,034,672
Tyrosine Kinase Inhibitor Compositions, Methods of Making and Methods of Use
Oct 2, 2039
US 12,714,713
Method of Treating Cancers with Alkyne Substituted Quinazoline Derivatives
Jan 6, 2043
20262031203620412043
7 pending applications: term is not computable until grant.Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Oct 2039 · High confidence
Also notable
Ends Jan 2043 · High confidence
Tyrosine Kinase Inhibitor Compositions, Methods of Making and Methods of Use
US 11,034,672
Granted 2021. Computed term ends 2039.
Method of Treating Cancers with Alkyne Substituted Quinazoline Derivatives
US 12,714,713
Granted 2026. Too new for citation comparison; protection runs to 2043. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
- Nov 3Assignment recorded on 1 record: Kumar, Santosh and 1 other to Black Diamond Therapeutics, Inc. Recorded Nov 3, 2026, executed Aug 27, 2025. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76615, frame 798.
- 2 of the patents on this record were granted since Aug 23, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Alkynyl Quinazoline Compounds | 1 in force | to Jan 2043 |
| Method of Treating Cancers with Alkyne Substituted Quinazoline Derivatives | 1 in force | to Jan 2043 |
| Quinoxaline Derivatives and Uses Thereof | 1 in force | to Dec 2042 |
| Tyrosine Kinase Inhibitor Compositions, Methods of Making and Methods of Use | 1 in force | to Oct 2039 |
Patents held now
Soonest term end first.
Showing 1 to 4 of 4
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,034,672 | Tyrosine Kinase Inhibitor Compositions, Methods of Making and Methods of Use In force · High confidence | In force | High confidence | |
| US 12,741,976 | Quinoxaline Derivatives and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,435,046 | Alkynyl Quinazoline Compounds In force · High confidence | In force | High confidence | |
| US 12,714,713 | Method of Treating Cancers with Alkyne Substituted Quinazoline Derivatives In force · High confidence | In force | High confidence |
Also on record, not counted in the 4: 7 applications pending · 3 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.